MODELING HEALTH AND ECONOMIC OUTCOMES ASSOCIATED WITH EXENATIDE ONCE-WEEKLY VERSUS INSULIN AND PIOGLITAZONE TREATMENT FOR TYPE-2 DIABETES

被引：0
|
作者：
Gaebler, J. A. [1 ]
Soto-Campos, G. [2 ]
Alperin, P. E. [3 ]
Hoogwerf, B. J. [4 ]
Wintle, M. [1 ]
Maggs, D. [1 ]
Han, J. [1 ]
Blickensderfer, A. [5 ]
Pencek, R. [1 ]
Bruhn, D. [6 ]
Peskin, B. R. [2 ]
机构：
[1] Amylin Pharmaceut Inc, San Diego, CA USA
[2] Archimedes Inc, San Francisco, CA USA
[3] Archimedes Inc, San Diego, CA USA
[4] Eli Lilly & Co, Indianapolis, IN 46285 USA
[5] Amylin Pharmaceut Inc, Chesterfield, MO USA
[6] Eli Lilly & Co, San Diego, CA USA
来源：
VALUE IN HEALTH | 2011年 / 14卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
下载
收藏
页码：A91 / A91
页数：1
相关论文
共 50 条
  • [1] Modeling Cardiovascular Health Outcomes Associated with Once-Weekly Exenatide Versus Traditional Therapies for Type 2 Diabetes
    Peskin, Barbara R.
    Shcheprov, Andrei V.
    Kalsekar, Anupama
    Boye, Kristina S.
    Bruce, Simon
    Gaebler, Julia A.
    DIABETES, 2010, 59 : A162 - A162
  • [2] Health and economic outcomes for exenatide once weekly, insulin, and pioglitazone therapies in the treatment of type 2 diabetes: a simulation analysis
    Gaebler, Julia A.
    Soto-Campos, Gerardo
    Alperin, Peter
    Cohen, Marc
    Blickensderfer, Amy
    Wintle, Matthew
    Maggs, David
    Hoogwerf, Byron
    Han, Jenny
    Pencek, Richard
    Peskin, Barbara
    VASCULAR HEALTH AND RISK MANAGEMENT, 2012, 8 : 255 - 264
  • [3] USING HEALTH OUTCOMES MODELING TO ASSESS THE BENEFIT-RISK PROFILE OF EXENATIDE ONCE-WEEKLY VERSUS INSULIN GLARGINE FOR PATIENTS WITH TYPE-2 DIABETES
    Garrison, L.
    Best, J. H.
    Robertson, J. C.
    Wenten, M.
    Bruhn, D.
    VALUE IN HEALTH, 2011, 14 (03) : A93 - A93
  • [4] Once-weekly exenatide as a treatment for Type 2 diabetes
    Schauerhamer, Marisa B.
    Gurgle, Holly
    McAdam-Marx, Carrie
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2015, 13 (06) : 611 - 626
  • [5] Once-weekly exenatide in type 2 diabetes
    Dinesh M. Parmar
    Shilpa P. Jadav
    International Journal of Diabetes in Developing Countries, 2011, 31 : 121 - 122
  • [6] Once-weekly exenatide in type 2 diabetes
    Parmar, Dinesh M.
    Jadav, Shilpa P.
    INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES, 2011, 31 (02) : 121 - 122
  • [7] Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
    Holman, Rury R.
    Bethel, M. Angelyn
    Mentz, Robert J.
    Thompson, Vivian P.
    Lokhnygina, Yuliya
    Buse, John B.
    Chan, Juliana C.
    Choi, Jasmine
    Gustavson, Stephanie M.
    Iqbal, Nayyar
    Maggioni, Aldo P.
    Marso, Steven P.
    Ohman, Peter
    Pagidipati, Neha J.
    Poulter, Neil
    Ramachandran, Ambady
    Zinman, Bernard
    Hernandez, Adrian F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (13): : 1228 - 1239
  • [8] Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes Reply
    Holman, Rury R.
    Bethel, M. Angelyn
    Hernandez, Adrian F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (25): : 2502 - 2502
  • [9] Once-Weekly Exenatide in Youth With Type 2 Diabetes
    Tamborlane, William, V
    Bishai, Raafat
    Geller, David
    Shehadeh, Naim
    Al-Abdulrazzaq, Dalia
    Manica Vazquez, Evelina
    Karoly, Eva
    Troja, Tunde
    Doehring, Orlando
    Carter, Debra
    Monyak, John
    Sjostrom, C. David
    DIABETES CARE, 2022, 45 (08) : 1833 - 1840
  • [10] Clinical effects of once-weekly exenatide for the treatment of type 2 diabetes mellitus
    Ryan, Gina J.
    Moniri, Nader H.
    Smiley, Dawn D.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (13) : 1123 - 1131
12345